Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials
Clinics
;
78: 100200, 2023. tab, graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1439927
ABSTRACT
Abstract Objectives:
Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute Kidney Injury (AKI). In this study, we aim to determine whether remdesivir use in COVID-19 patients increases the risk of AKI.Methods:
PubMed, Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, medRxiv, and bio-Rxiv were systematically searched until July 2022, to find Randomized Clinical Trials (RCT) that evaluated remdesivir for its effect on COVID-19 and provided information on AKI events. A random-effects model metaanalysis was conducted and the certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation. The primary outcomes were AKI as a Serious Adverse Event (SAE) and combined serious and non-serious Adverse Events (AE) due to AKI.Results:
This study included 5 RCTs involving 3095 patients. Remdesivir treatment was not associated with a significant change in the risk of AKI classified as SAE (Risk Ratio [RR] 0.71, 95% Confidence Interval [95% CI] 0.43‒1.18, p = 0.19, low-certainty evidence) and AKI classified as any grade AEs (RR = 0.83, 95% CI 0.52‒1.33, p = 0.44, low-certainty evidence), compared to the control group.Conclusion:
Our study suggested that remdesivir treatment probably has little or no effect on the risk of AKI in COVID-19 patients.
Full text:
Available
Index:
LILACS (Americas)
Type of study:
Controlled clinical trial
/
Practice guideline
/
Systematic reviews
Language:
English
Journal:
Clinics
Journal subject:
Medicine
Year:
2023
Type:
Article
Affiliation country:
Canada
/
Iran
Institution/Affiliation country:
Isfahan University of Medical Sciences/IR
/
Shiraz University of Medical Sciences/IR
/
University of Manitoba/CA
Similar
MEDLINE
...
LILACS
LIS